Roland Schoop

Summary

Country: Switzerland

Publications

  1. ncbi Anti-viral properties and mode of action of standardized Echinacea purpurea extract against highly pathogenic avian influenza virus (H5N1, H7N7) and swine-origin H1N1 (S-OIV)
    Stephan Pleschka
    Institute for Medical Virology, Justus Liebig University Giessen, Giessen, Germany
    Virol J 6:197. 2009
  2. ncbi Echinacea in the prevention of induced rhinovirus colds: a meta-analysis
    Roland Schoop
    A Vogel Bioforce AG, Roggwil, Switzerland
    Clin Ther 28:174-83. 2006
  3. ncbi Pharmacokinetics of the main alkamides after administration of three different Echinacea purpurea preparations in humans
    Karin Woelkart
    Institute of Pharmaceutical Sciences, Department of Pharmacognosy, Karl Franzens University, Graz, Austria
    Planta Med 74:651-6. 2008
  4. ncbi Echinacea alkylamides modulate TNF-alpha gene expression via cannabinoid receptor CB2 and multiple signal transduction pathways
    Juerg Gertsch
    Swiss Federal Institute of Technology, Institute of Pharmaceutical Sciences, Wolfgang Pauli Str 10 CH 8093 Zurich, Switzerland
    FEBS Lett 577:563-9. 2004

Collaborators

  • Andy Suter
  • Jürg Gertsch
  • Stephan Pleschka
  • Karin Woelkart
  • Michael Stein
  • James B Hudson
  • Fritz Pinl
  • Rudolf Bauer
  • Eckhard Beubler
  • Peter Dittrich

Detail Information

Publications4

  1. ncbi Anti-viral properties and mode of action of standardized Echinacea purpurea extract against highly pathogenic avian influenza virus (H5N1, H7N7) and swine-origin H1N1 (S-OIV)
    Stephan Pleschka
    Institute for Medical Virology, Justus Liebig University Giessen, Giessen, Germany
    Virol J 6:197. 2009
    ..As an alternative approach to the common anti-virals we studied in more detail a commercial standardized extract of the widely used herb Echinacea purpurea (Echinaforce, EF) in order to elucidate the nature of its anti-IV activity...
  2. ncbi Echinacea in the prevention of induced rhinovirus colds: a meta-analysis
    Roland Schoop
    A Vogel Bioforce AG, Roggwil, Switzerland
    Clin Ther 28:174-83. 2006
    ..Experimental infection studies allow for the standardization of time to initiation of treatment, virus type and dose, and immune competence of volunteers...
  3. ncbi Pharmacokinetics of the main alkamides after administration of three different Echinacea purpurea preparations in humans
    Karin Woelkart
    Institute of Pharmaceutical Sciences, Department of Pharmacognosy, Karl Franzens University, Graz, Austria
    Planta Med 74:651-6. 2008
    ..22 +/- 0.15 ng/mL after taking Echinaforce Junior tablets and 0.23 +/- 0.16 ng/mL after administration of an Echinacea sore throat spray. The areas under the curve were 0.22 ng/mL x h, 0.20 ng/mL x h and 0.23 ng/mL x h, respectively...
  4. ncbi Echinacea alkylamides modulate TNF-alpha gene expression via cannabinoid receptor CB2 and multiple signal transduction pathways
    Juerg Gertsch
    Swiss Federal Institute of Technology, Institute of Pharmaceutical Sciences, Wolfgang Pauli Str 10 CH 8093 Zurich, Switzerland
    FEBS Lett 577:563-9. 2004
    ..This study is the first to report a possible molecular mechanism of action of Echinacea, highlighting the role of alkylamides as potent immunomodulators and potential ligands for CB2 receptors...